Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant (EVEROSTAT)

January 29, 2009 updated by: Fundacion Investigacion y Desarrollo

Prospective and Randomized Study to Evaluate the Effect of Everolimus in the Clinical and Intra-Cardiac Ecography Progression of Heart Graft Vascular Illness.

The purpose of this study is to evaluate if there is a significantly less incidence of major clinical events due to graft vascular illness in recipients of a cardiac transplant on treatment with an immunosuppressive combination, which includes Everolimus, compared to those that continue the previously used immunosuppressive treatment.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, randomized, multicentre, open and controlled study, to evaluate the efficacy and safety of everolimus combined with cyclosporin for microemulsion and steroids according to medical judgement, opposite to the usual therapy which the patient already has received (typically: ciclosporin + azathioprine or mycophenolate mofetil + steroids according to the judgement of the doctor) for patients receiving a cardiac orthotopic transplant since at least 12 months. The patients will be randomized in a 2:1 proportion (everolimus:control), in order to make it possible for the majority of patients to receive the potentially active treatment in a lethal illness for which there is not efficient known treatment up to date.

The study duration will be 2 years of follow-up for each patient. At the end of this period, the patients will be offered the possibility to maintain the immunosuppressive treatment to which they have been assigned, and periodic revisions will be made each 3-6 months.

The two treatment groups are:

Group I - Everolimus twice a day v.o. + cyclosporin for microemulsion in reduced doses +/- steroids.

Group II - Cyclosporin for microemulsion + azathioprine or mycophenolate mofetil +/- steroids (the same administration schedule and medication which the patient received earlier).

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Barcelona, Spain, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Spain, 08041
        • Hospital Santa Creu i Sant Pau
      • Barcelona, Spain, 08907
        • Hospital de Bellvitge
      • Madrid, Spain, 28041
        • Hospital 12 de Octubre
      • Madrid, Spain, 28007
        • Hospital Gregorio Marañón
      • Madrid, Spain, 28035
        • Hospital Puerta de Hierro
    • Cantabria
      • Santander, Cantabria, Spain, 39008
        • Hospital Marqués de Valdecilla
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Clinica Universitaria de Navarra

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients suffering a heart transplantation at least 12 months before the inclusion.
  • Patients with significant graft vascular cardiac illness.

Exclusion Criteria:

  • Patients who received more than one solid organ.
  • Hypersensibility to everolimus.
  • Patients with expected surviving less than 6 months.
  • Analytic abnormality significant (platelets < 70.000 plat./mm3, WBC<4.000./mm3, creatinine > 2,5 mg/dl)
  • Neoplasm and/or severe systemic illness.
  • Mental significant illness.
  • Patients who have received sirolimus or everolimus in any moment after transplant.
  • Pregnant or lactating woman.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
Everolimus 2 times per day + cyclosporin low dose +/- steroids
Everolimus 2 times per day, v.o., 2 years treatment.
Other Names:
  • Certican
ACTIVE_COMPARATOR: 2
Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
2 times per day during 2 years
Other Names:
  • Cellcept
  • Imurel

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of subjects that present at least one major clinical event due to graft vascular illness during the first year of the study on both treatment arms.
Time Frame: December 2010
December 2010

Secondary Outcome Measures

Outcome Measure
Time Frame
Intra-coronary ultrasound, safety and adverse events, Nt-proBNP, left ventricular systolic function, coronary stenosis.
Time Frame: December 2010
December 2010

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Javier Segovia, cardiologist, Hospital Puerta de Hierro
  • Principal Investigator: Nicolás Manito, Cardiologist, Hospital Universitari de Bellvitge
  • Principal Investigator: Gregorio Rábago, Cardiologist, Clinica Universitaria de Navarra
  • Principal Investigator: Francisco González-Vílchez, Cardiologist, Hospital Marqués de Valdecilla
  • Principal Investigator: Juan Delgado, Cardiologist, Hospital 12 de Octubre
  • Principal Investigator: Juan Fernández Yañez, Cardiologist, Gregorio Maranon Hospital
  • Principal Investigator: Sonia Mirabet, Cardiologist, Hospital Santa Creu i Sant Pau
  • Principal Investigator: Eulalia Roig, Cardiologist, Hospital Clinic of Barcelona

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2006

Primary Completion (ANTICIPATED)

June 1, 2010

Study Completion (ANTICIPATED)

June 1, 2010

Study Registration Dates

First Submitted

June 9, 2008

First Submitted That Met QC Criteria

June 10, 2008

First Posted (ESTIMATE)

June 11, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

January 30, 2009

Last Update Submitted That Met QC Criteria

January 29, 2009

Last Verified

January 1, 2009

More Information

Terms related to this study

Other Study ID Numbers

  • EVEROSTAT

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.